MOEXIPRIL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Moexipril Hydrochloride patents expire, and what generic alternatives are available?
Moexipril Hydrochloride is a drug marketed by Apotex Inc, Chartwell Rx, Glenmark Pharms Ltd, Teva, Glenmark Pharms, and Heritage. and is included in eight NDAs.
The generic ingredient in MOEXIPRIL HYDROCHLORIDE is hydrochlorothiazide; moexipril hydrochloride. There are two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; moexipril hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MOEXIPRIL HYDROCHLORIDE?
- What are the global sales for MOEXIPRIL HYDROCHLORIDE?
- What is Average Wholesale Price for MOEXIPRIL HYDROCHLORIDE?
Summary for MOEXIPRIL HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 8 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 59 |
| Clinical Trials: | 6 |
| Patent Applications: | 1,690 |
| DailyMed Link: | MOEXIPRIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MOEXIPRIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Nebraska | Phase 4 |
| Teva Pharmaceuticals USA | Phase 1 |
| UCB Pharma | Phase 2 |
Pharmacology for MOEXIPRIL HYDROCHLORIDE
| Drug Class | Angiotensin Converting Enzyme Inhibitor |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |

